Heat Biologics (NASDAQ:HTBX) Upgraded to “Buy” at ValuEngine

Heat Biologics (NASDAQ:HTBX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Wednesday, ValuEngine reports.

Shares of Heat Biologics stock opened at $0.45 on Wednesday. The company’s fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.58. The stock has a market capitalization of $15.33 million, a PE ratio of -0.50 and a beta of 1.80. Heat Biologics has a 1-year low of $0.35 and a 1-year high of $1.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.29 and a quick ratio of 3.29.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. lifted its stake in Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,327,660 shares of the biopharmaceutical company’s stock after buying an additional 84,400 shares during the quarter. Vanguard Group Inc. owned approximately 3.90% of Heat Biologics worth $909,000 at the end of the most recent reporting period. 4.93% of the stock is currently owned by institutional investors.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Featured Story: What Factors Can Affect Return on Equity?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.